APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 213 filers reported holding APELLIS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,623,733 | -94.8% | 68,973 | -87.6% | 0.00% | -94.2% |
| Q2 2023 | $50,771,032 | +86.4% | 557,311 | +35.0% | 0.05% | +79.3% |
| Q1 2023 | $27,231,784 | +3983.0% | 412,853 | +3100.9% | 0.03% | +2800.0% |
| Q4 2022 | $666,956 | -95.1% | 12,898 | -93.5% | 0.00% | -93.8% |
| Q3 2022 | $13,480,000 | +6412.1% | 197,364 | +4218.7% | 0.02% | – |
| Q2 2022 | $207,000 | -87.7% | 4,570 | -86.2% | 0.00% | -100.0% |
| Q1 2022 | $1,678,000 | -6.3% | 33,034 | -12.8% | 0.00% | +100.0% |
| Q4 2021 | $1,791,000 | -28.0% | 37,890 | -49.8% | 0.00% | -50.0% |
| Q3 2021 | $2,489,000 | -83.9% | 75,522 | -69.2% | 0.00% | -84.6% |
| Q2 2021 | $15,486,000 | +7.2% | 245,029 | -27.2% | 0.01% | -7.1% |
| Q1 2021 | $14,445,000 | -39.0% | 336,643 | -18.7% | 0.01% | -33.3% |
| Q4 2020 | $23,684,000 | +103.4% | 414,062 | +7.3% | 0.02% | +75.0% |
| Q3 2020 | $11,642,000 | -33.0% | 385,866 | -27.4% | 0.01% | -42.9% |
| Q2 2020 | $17,367,000 | +75.3% | 531,761 | +43.8% | 0.02% | +40.0% |
| Q1 2020 | $9,905,000 | +118.0% | 369,733 | +149.1% | 0.02% | +200.0% |
| Q4 2019 | $4,544,000 | +1601.9% | 148,407 | +1241.2% | 0.01% | – |
| Q3 2019 | $267,000 | – | 11,065 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| AJU IB Investment Co., Ltd. | 1,114,962 | $63,776,000 | 24.13% |
| Octagon Capital Advisors LP | 548,374 | $31,367,000 | 10.87% |
| Ghost Tree Capital, LLC | 325,000 | $18,590,000 | 4.14% |
| Burrage Capital Management LLC | 81,357 | $4,654,000 | 3.55% |
| Aufman Associates Inc | 53,642 | $3,068,000 | 2.75% |
| ACUTA CAPITAL PARTNERS, LLC | 167,054 | $9,555,000 | 2.60% |
| Cormorant Asset Management, LP | 1,866,108 | $106,741,000 | 2.54% |
| Tri Locum Partners LP | 121,409 | $6,945,000 | 2.52% |
| venBio Partners LLC | 490,471 | $28,055,000 | 2.48% |
| HHLR ADVISORS, LTD. | 5,028,289 | $287,618,000 | 2.29% |